Several randomized controlled studies, systematic reviews, and meta-analyses have shown good outcomes in terms of better survival and a reduced rate of complications in patients with chronic obstructive pulmonary disease (COPD) treated with NIV for acute exacerbations of chronic respiratory failure.
2,3 Based on the above data, NIV is recommended as the first-line ventilation strategy in COPD exacerbation, with different timing and setting according to the severity of acute respiratory failure (ARF). 1 Most patients PATIENTS AND METHODS This was a multicenter, prospective clinical study. Patients were recruited over 10 years from 3 Italian respiratory monitoring units (RMUs): General Hospital in Sestri Levante, U. Parini Hospital in Aosta, and Villa Scassi Hospital in Genoa. The 3 RMUs have 4 noninvasive monitored beds each and admit patients with severe respiratory failure who require NIV. We enrolled 1809 patients admitted for hypercapnic ARF due to COPD exacerbation and treated with NIV. The study was conducted at an RMU from December 2002 to December 2012. It was approved by local ethics committees, and every patient gave written informed consent to participate in the study. Patients who did not give informed consent or who had a "do not intubate" advance directive were excluded from the study. During the study period, we followed all consecutive patients with an exacerbation of COPD undergoing an episode of ARF. Diagnosis of COPD was based on the presence of airflow obstruction in previous pulmonary function tests and the severity of the diseases according to the Global Initiative for Chronic Obstructive Lung Disease criteria. 15 The RMUs were equipped with both a ventilator specifically designed for NIV (Philips Respironics Vision BiPap, Philips Respironics V60, Versamed Ivent 201 AB, Care Fusion Vela, Bellavista Imtmedical) and invasive ventilation (Philips Respironics Esprit, Versamed Ivent 201 IC, Care Fusion Vela, Bellavista Imtmedical), which made it possible to switch from NIV to invasive ventilation at any moment. The criteria for initiating NIV as well as the exclusion criteria were described previously. 16 Expiratory positive airway pressure was initially set at a level of 4 cm H 2 O and was increased by 1 to 2 cm H 2 O if needed to achieve an oxygen arterial pressure (PaO 2 ) of 60 mmHg or less or an SpO 2 of 90% or less. Inspiratory positive airway pressure was increased to 10 cm H 2 O at increments of 2 to 3 cm H 2 O to obtain a tidal volume of 6 to 8 ml/kg and a respiratory rate of 30 breaths/min or less. Moreover, patients scheduled for NIV did not fulfill any criteria for emergency intubation (eg, respiratory pauses, agitation requiring sedation, hemodynamic instability with systolic blood pressure of less than 90 mmHg, and a heart rate of less than 40 bpm). During the study, physician teams and respiratory therapists remained the same in each center, while approximately 25% of the nursing team were substituted. The nurse-to-patient ratio did not change during the study and was 1:4 during the day shift and 1:6 during the night shift. In addition, the number of physicians did not change during the study period (2 chest physicians during the day shift and 1 internal medicine physician during the night shift and a chest physician available on call). Data on sex, age, presence of comorbidities, severity of illness (Simplified Acute Physiology Score [SAPS II]), impaired sensory perception (Kelly-Matthay scale), results of arterial blood gas (ABG) analysis at baseline and after 1 hour of NIV, 16 and ventilator settings requiring NIV should be managed in an intensive care setting. 4 Success of NIV depends mainly on the setting in which the procedure is performed. An intensive care unit (ICU) is recognized to be the safest setting in this case, but owing to the shortage of beds and an increasing number of indications for admission to the ICU, NIV is now performed also in other settings, especially in emergency departments and general wards as well as in step-down units and even other settings prior to hospital admission. 5-10 It has been shown that NIV can be safely used in a non-ICU respiratory ward in COPD patients suffering from a mild acute exacerbation with mild respiratory acidosis (pH >7. 30) .
11 According to a recent Italian survey, NIV is also extensively and successfully used in non-ICU wards in COPD patients with moderate to severe ARF (pH >7.25).
12 In clinical practice, the strategies for NIV may differ between medical centers.
1
Better outcomes in patients undergoing NIV depend on whether a number of conditions have been met. Most importantly, all patients require close monitoring especially at the beginning of NIV. In addition, a team that performs the procedure should have adequate training and expertise. The ability to perform NIV improves over time and, according to the literature, with increasing experience, the team becomes more skilled to treat more severe episodes of ARF, while maintaining high success rates.
1,13,14
The aim of our study was to examine the effectiveness of NIV in terms of mortality rates and the need for intubation in a non-ICU setting and to investigate the predictors of NIV success or failure, considering team expertise, characteristics of patients, and setting. exacerbations of COPD and included in the final analysis. The most important cause of exacerbation was respiratory infection (66.3%) followed by cardiac failure (24.1%) and pulmonary embolism (5.92%). The majority of the patients (66.6%) had 1 or more comorbidities; 25.5% of the patients underwent previous long-term home oxygen therapy and 3.6% underwent NIV. The characteristics of the patients on admission are summarized in TABLE 1 . NIV was performed for 62 ±29 hours and daily application lasted more than 20 hours for the first 24 hours and was then gradually reduced until weaning was achieved. The most used types of ventilation were pressure support ventilation (45. 6%) and bilevel positive airway pressure / spontaneous-timed (38. 6%).
Considering that we have almost a constant annual number of patients treated with NIV at our centers, we have noted that the severity of the ARF episodes defined by the severity of acidosis (PaCO 2 and pH on admission) and illness (SAPS II) worsened progressively and significantly during the study period with a difference between the first 5 years (December Factors associated with hospital mortality Because most patients who were intubated died (58 of 72 [80.5%]), we considered the factors associated with intubation and hospital mortality together. The stepwise regression analysis including were recorded. Failure of NIV was defined as death or need of intubation as previously reported.
16,17 The flowchart of patients in the study is presented in the FIGURE.
Outcomes The primary outcomes were intubation and mortality rates in patients admitted to RMUs during the study period (NIV failure). The secondary outcomes were potential predictors of hospital mortality and the need for intubation. The duration of NIV, length of hospital stay, and 180-day mortality were also considered.
Statistical analysis Continuous variables were analyzed using regression analysis and categorical variables were compared using the χ 2 test. Stepwise logistic regression was used to identify the variables associated with intubation and hospital mortality. A P value of 0.05 or less was considered statistically significant. Data analysis was performed using the R-Project version 2.13.2 statistical software. but patient monitoring is crucial if the procedure is to be successful. Specifically, early identification of NIV failure is essential to reduce mortality, and careful consideration is needed before switching to invasive ventilation late in the course of an exacerbation.
1,19
Predicting outcomes, particularly negative ones, following the use of NIV in the acute setting, is essential to assist physicians with decision making. 19 Several studies have demonstrated that patients with severe acidosis, lower scores of daily living activities, and associated complications of critical illness are less likely to benefit from NIV. 1,2,19,22-25 However, ventilator interface and tolerability with an improvement in arterial pH, respiratory rate, and hemodynamic stability indicate a short-term favorable outcome. 1,2,13,17,19,22-25 In a study of 240 unselected patients undergoing ward-based NIV, Miller et al. 26 demonstrated that an improvement in pH within 1 hour after NIV predicted survival until hospital discharge with a sensitivity of 82%, which is in line with our findings. 19, 26 Our "real-life" data have shown that patients with fewer comorbidities, less severe illness, and an improvement in ABG parameters within 1 hour after NIV are more likely to have a successful outcome. The intubation and hospital mortality rates (6.6% and 5.3%, respectively) were generally among the lowest reported in the literature 27 and decreased gradually over the study period, while patients in progressively more severe conditions were admitted to our RMUs. Our data have also confirmed the importance of a chart of failure risk described by Confalonieri et al. 28 Patients with more severe illness, and particularly those in whom pH does not improve to 7.25 or higher within 2 hours after NIV, have a high risk of failure. 16, 29, 30 On the other hand, the probability of NIV success increases in relation to the appropriate choice of ventilator modality and interface, the level of team experience, the level of patient's understanding, and advanced age.
1,16,29,31-33
Ozyilmaz et al. 33 identified the following nonpatient related risk factors for NIV failure: 1) timing (ie, when NIV is performed); 2) the setting (ie, where NIV is performed) and choice of ventilator (dedicated NIV ventilators perform better than ICU ventilators, particularly in terms of leak compensation and patient-ventilator synchrony); and the factors used in the univariate analysis showed that SAPS II on admission, the presence of comorbidities, pH on admission and after 1 hour of NIV, and the PaO 2 /FiO 2 ratio on admission were independently associated with hospital mortality in the overall population (TABLE 3) . DISCUSSION 
Chandra et al.
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3) expertise of the staff. In addition, much attention has been paid to the development of new interfaces to increase tolerance and patient comfort, since mask intolerance remains the major cause of NIV failure. 33 An oro-nasal mask is generally the most common, followed by a nasal mask, helmet, and mouthpiece. These interfaces have a number of advantages and disadvantages, and, in case of poor tolerance, it is reasonable to apply the so called rotating strategy. 33 In this context, a skilled and experienced staff may treat more severe patients with better outcomes. 13,31 Moreover, an expert team may be more experiences in the management of pain, agitation, and sleep disturbances caused by prolonged duration of mechanical ventilation. 34 To our knowledge, only 1 study has examined the importance of a team's experience and skill in NIV. 35 Although it is difficult to define an experienced team, it should be more often considered as an important factor in the outcome of NIV treatment together with various other clinical factors.
36
Our study has several limitations. First, the causes of respiratory infections were not investigated and the data are not available. The presence of pneumonia has already been reported as a predictor of NIV failure, together with a lack of improvement of pH. 29, 36 Second, the criteria of intubation were not standardized a priori, as for a randomized controlled trial, but each center followed its institutional guidelines (which reflects the "real-life" setting). Third, we only considered the presence or absence of comorbidities, without investigating their type or number in individual patients or their role in determining NIV failure. Finally, the study was performed by teams experienced in NIV and used to manage a large number of patients per year using dedicated NIV ventilators. Therefore, our data cannot be generalized.
In summary, this observational study has highlighted the factors associated with patient outcome when using NIV for a hypercapnic exacerbation of COPD in the "real-life" setting. The expertise of the team as well as the identification of risk factors for NIV failure may allow to treat patients with more severe exacerbations and improve success rates.
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